**PP001**

**Label-free quantitative proteomic analysis of the secretomes from cholangiocarcinoma cell line, HuCCA-1**

**Chris Verathamjamras1, Daranee Chokchaichamnankit1, Kamolwan Watcharatanyatip1, Churat Weeraphan1,2, Voraratt Champattanachai1, Jisnuson Svasti1,3, and Chantragan Srisomsap1,**\*

1. Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok 10210, Thailand
2. Department of Molecular Biotechnology and Bioinformatics, Faculty of Science, Prince of Songkla University, Songkla 90110, Thailand
3. Applied Biological Sciences Program, Chulabhorn Graduate Institute, Bangkok 10210, Thailand

\***Email**: xxxxx@xxx.xx.xx

**ABSTRACT**

Cancer is a global life-threatening disease with high morbidity and mortality rates. As reported from …………………

This research was supported by ………

**Keywords:** cholangiocarcinoma, label-free, proteomic, secretomes

**INTRODUCTION**

The introduction should be as concise as possible, without subheadings. It introduction should provide an adequate background, the importance and the objectives of the work.

Interleukin-2 is a potent growth factor produced by activated T cells and stimulates a number of immune cells [1, 2]. It also enhances ……………

**MATERIALS AND METHODS**

*Subheading 1*

Description.

*Subheading 2*

Description.

*Subheading 3*

Description.

**RESULTS**

*Subheading 1*

Description. As illustrated in **Fig. 1A**, expression levels of drug transporters in wild type cell line were greater than that of mutant cell line, and these correlated with drug susceptibility profiles of the cell lines (**Fig. 1B and 1C**), the IC50 values of each drug were shown in **Table 1**.

 According to previous studies, the …

****

**Figure 1** Figure title. Figure descriptions……..

*Subheading 2*

Description. The results are shown in Table 1.

**Table 1** The table title**.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

a Footnotes should be written in Times New Roman, 12 points, regular, justified to both sides,

 and placed below the table.

*Subheading 3*

Description.

**DISCUSSION AND CONCLUSION**

Discussion is for interpretation of the results. Discuss principles and relationship. Point out exception. Show agreement/disagreement with published research work. A combined Results and Discussion section is often appropriate.

Conclusion is to describe the conductions and/or the significance of the work.

**ACKNOWLEDGEMMENTS**

Provide the names of those who have providing help during the research (including funding agencies).

**REFERENCES**

1. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28(3):109-23.
2. Mott HR, Driscoll PC, Boyd J, Cooke RM, Weir MP, Campbell ID. Secondary structure of human interleukin 2 from 3D heteronuclear NMR experiments. Biochemistry. 1992;31(33):7741-4.
3. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance. Int J Oncol. 2012;40(3):639-44.
4. Meisenberg G, Simmons WH. Principles of medical biochemistry. 2nd ed. Mosby Elsevier; 2006.
5. Beizer JL, Timiras ML. Pharmacology and drug management in the elderly. In: Timiras PS, editor. Physiological basis of aging and geriatrics. 2nd ed. Boca Raton: CRC Press; 1994. p. 279-84.

**GENERAL FORMATTING:**

**File format:** Microsoft Word (.docx) only;

 **Save as >> Save as type: "** **Word Document (\*.docx)"**

**Paper size:** A4 ("8.27 x 11.69 in" or "210 x 297 mm")

**Page layout:** Portrait, single column.

**Margins:** 1 inch (2.54 cm) at all sides.

**Font:** **Times New Roman**.

**Line spacing:** **1.0 (single-spaced; spacing before = 0 pt, after = 0 pt) throughout the text**.

**Title: Sentence case, 14-point (bold text)**.

**Authors: 12-point (bold text).**

Presenting author should be underlined.

Give an asterisk (\*) at the corresponding author.

**Affiliations:** 12-point (regular text).

**Headings:** *e.g.,* ABSTRACT, INTRODUCTION, RESULTS, *etc.*

**CAPITAL LETTER, 12-point (bold text).**

*Do not leave a line between the headings and the following text.*

**Abstract body:** 12-point (regular text). Do not exceed **250 words**.

**Text body:** 12-point (regular text).

**Paragraph:** Start with indentation and *Justified to both sides.*

**Abbreviations:** Spelled out, in parenthesis, in the first use in the text.

**Unit:** SI system.

**References:** **Vancouver style**. In addition, **please be sure to check the format of in-line reference as follow**: indicate references by number(s) in square brackets in the order of their appearance in the text and in line with text **(e.g.** some text … **[1]**, some text … **[2,4]**, etc.**)**.

**PROCEEDING GUIDELINES:**

All Proceedings must be **written in ENGLISH (either American English or British English, but not a mixture of these)**. Graphs, figures and tables are not allowed.

Proceeding file must contain TITLE, AUTHORS, AFFILIATIONS, ABSTRACT, KEYWORDS (3 - 6 keywords), INTRODUCTION, MATERIALS AND METHODS, RESULTS, DISCUSSION AND CONCLUSION, and REFERENCES.

Indicate **Presenting Author** with **Underline**

Indicate **Corresponding Author** with **Asterisk (\*)** after the name

FIGURES and TABLES must be INCLUDED in the MANUSCRIPT.

Standard abbreviations can be used throughout. Any special or unusual abbreviations should be spelled out in full at first mention, followed by the abbreviation in parentheses. It is recommended that you use abbreviations minimally in your abstract.

**Greek characters** (*e.g.,* alpha, beta) in both the title and the text **should be spell out**.

Total number of pages should be 4 - 8 pages.

Please be reminded that the research work to be submitted for Proceeding Publication must contain PROTEIN RELATED experiments (e.g. work with only gene cloning may be rejected).

Check carefully for any misspellings and/or typographical errors.

**When fill-in the online-submission form, if symbol characters are used, please try copy & paste such characters from your document file (e.g. Microsoft Word).**

**An** **EXTRA 1,000 BAHT** **will be CHARGED to the REGISTRANT for FULL PAPER PUBLICATION (ISBN: xxx-xxx-xxx-x) once your proceeding is ACCEPTED**.

**ACCEPTED PROCEEDING must also be presented as a POSTER** unless it is selected as an oral.